Oramed Announces Closing of $18.1 Million Registered Direct Offering

NEW YORK, July 6, 2018 /PRNewswire/ — Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) (TASE: ORMP), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today the closing of its previously-announced registered direct offering with several healthcare-focused institutional investors. Oramed has sold $18.1 million of shares of common stock and warrants to purchase […]

Join our mailing list

Skip to content